<DOC>
	<DOCNO>NCT00030719</DOCNO>
	<brief_summary>RATIONALE : Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . Combining chemotherapy peripheral stem cell transplant may allow doctor give high dos chemotherapy drug kill tumor cell . Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining isotretinoin monoclonal antibody may kill remain tumor cell follow surgery . It yet know treatment regimen effective treat neuroblastoma . PURPOSE : This randomized phase III trial study well combination chemotherapy without filgrastim surgery , high-dose chemotherapy , radiation therapy follow isotretinoin without monoclonal antibody work treat patient neuroblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Filgrastim Before Surgery , High-Dose Chemotherapy , Radiation Therapy Followed Isotretinoin With Without Monoclonal Antibody Treating Patients With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy myeloablative therapy busulfan melphalan v carboplatin , etoposide , melphalan , term 3- 5-year event-free survival ( EFS ) , progression-free survival ( PFS ) , overall survival ( OS ) , patient high-risk neuroblastoma . - Compare 3-year EFS patient treat isotretinoin without monoclonal antibody Ch14.18 myeloablative therapy . - Determine response metastatic site induction chemotherapy patient . - Determine effect metastatic disease response induction chemotherapy EFS , PFS , OS patient . - Compare toxicity episode febrile neutropenia patient treat induction chemotherapy without filgrastim ( G-CSF ) . - Determine effect elective hematopoietic support G-CSF induction chemotherapy peripheral blood stem cell collection patient . - Compare acute long-term toxic effect 2 myeloablative therapy regimens patient . - Determine effect radiotherapy pre-surgical tumor volume primary site local control , EFS , PFS , OS patient . - Determine tolerability isotretinoin without monoclonal antibody Ch14.18 myeloablative therapy patient . OUTLINE : This randomize , multicenter study . Patients stratify accord disease stage ( 2 3 MycN amplification vs 4 ) . Patients randomize 1 8 treatment arm : Arm I : - Patients receive induction chemotherapy comprise vincristine IV , carboplatin IV 1 hour , etoposide IV 4 hour day 1 41 ; vincristine IV cisplatin IV 24 hour day 11 , 31 , 51 , 71 ; vincristine IV day 21 61 cyclophosphamide IV etoposide 4 hour day 21 , 22 , 61 , 62 . Patients receive filgrastim ( G-CSF ) subcutaneously day 3-8 , 12-18 , 23-28 , 32-38 , 43-48 , 52-58 , 63-68 , 72 peripheral blood stem cell ( PBSC ) collection . - Patients undergo PBSC collection begin day 80 . Patients undergo surgery day 95 . - Patients receive myeloablative therapy comprise oral busulfan 4 time daily day -6 -3 melphalan IV 15 minute day -2 . Patients undergo PBSC infusion day 0 . - Patients undergo radiotherapy 14 fraction 21 day . - Beginning within 30 day radiotherapy , patient receive oral isotretinoin twice daily day 1-14 . Treatment repeat every 28 day 6 course . Arm II : - Patients receive induction chemotherapy arm I , G-CSF . Patients undergo PBSC collection surgery arm I . Patients receive myeloablative therapy undergo PBSC infusion arm I . Patients undergo radiotherapy arm I . - Patients receive oral isotretinoin twice daily day 1-14 monoclonal antibody Ch14.18 IV 8 hour day 1-5 . Treatment repeat every 28 day 6 course isotretinoin every 28 day 5 course monoclonal antibody Ch14.18 . Arm III : - Patients receive induction chemotherapy G-CSF arm I . Patients undergo PBSC collection surgery arm I . Patients receive myeloablative therapy undergo PBSC infusion arm I . Patients undergo radiotherapy arm I . Patients receive isotretinoin arm I . Arm IV : - Patients receive induction chemotherapy arm II . Patients undergo PBSC collection surgery arm I . Patients receive myeloablative therapy undergo PBSC infusion arm I . Patients undergo radiotherapy arm I . Patients receive isotretinoin monoclonal antibody Ch14.18 arm II . Arm V : - Patients receive induction chemotherapy G-CSF arm I . - Patients receive myeloablative therapy comprise carboplatin IV continuously etoposide IV continuously day -7 -4 melphalan IV 15 minute day -7 -5 . Patients undergo PBSC infusion day 0 . - Patients undergo radiotherapy arm I . Patients receive isotretinoin arm I . Arm VI : - Patients receive induction chemotherapy arm II . Patients receive myeloablative therapy undergo PBSC infusion arm V. Patients undergo radiotherapy arm I . Patients receive isotretinoin monoclonal antibody Ch14.18 arm II . Arm VII : - Patients receive induction chemotherapy G-CSF arm I . Patients receive myeloablative therapy undergo PBSC infusion arm V. Patients undergo radiotherapy arm I . Patients receive isotretinoin arm I . Arm VIII : - Patients receive induction chemotherapy arm II . Patients receive myeloablative therapy undergo PBSC infusion arm V. Patients undergo radiotherapy arm I . Patients receive isotretinoin monoclonal antibody Ch14.18 arm II . Patients treatment arm follow every 6 month 3 year annually 2 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : Approximately 175 patient per year accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis neuroblastoma accord International Neuroblastoma Staging System Stage 2 3 MycN amplification Stage 4 Tumor material available determination biological prognostic factor PATIENT CHARACTERISTICS : Age : 1 20 diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 3 time normal ALT le 3 time normal Renal : Creatinine le 1.5 mg/mL Creatinine clearance and/or glomerular filtration rate least 60 mL/min Cardiovascular : Shortening fraction least 28 % OR Ejection fraction least 55 % No clinical congestive heart failure Pulmonary : Chest xray normal Oxygen saturation normal Other : HIV negative No Brock grade 2 great No uncontrolled infection require IV antiviral , antibiotic , antifungal Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 1 prior chemotherapy regimen localize unresectable disease No concurrent anthracyclines No concurrent chemotherapy Endocrine : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>